

**PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY**

LOXICOM 5 mg/mL INJECTION

COMPOSITION

Clear yellow solution for injection containing 5mg meloxicam per mL (and 150mg of ethanol as preservative).

ACTION

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.

INDICATIONS

Dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs.

Cats - reduction of pain after surgery. Management of febrile conditions in combination with appropriate antibiotics.

DIRECTIONS FOR USE

This product is contraindicated for use in pregnant or lactating animals. This product is contraindicated for use in animals less than 6 weeks of age. This product is contraindicated for use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product.

As for all NSAIDs use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

PRECAUTIONS

Cats: Loxicom should be used as a single dose of 0.3 mg meloxicam/kg. Safety trials have demonstrated that meloxicam, when administered subcutaneously at 0.3mg/kg at 24 hour intervals for 3 consecutive days in cats, resulted in no side effects in trial animals.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Loxicom must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pre-treatment with other anti-inflammatory drugs prior to the use of Loxicom may result in additional or increased adverse effects. Accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Loxicom 5mg/mL Injection. The treatment free period, however, should take into account the pharmacokinetic properties of the drugs previously used.

Parenteral administration of Loxicom 5mg/mL Injection is well tolerated without local adverse reactions. Typical adverse reactions of NSAIDs include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. These side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious.

Hypovolaemia or hypotension should be corrected prior to use of the product. In case of overdosing a symptomatic treatment should be initiated.

DOSAGE AND ADMINISTRATION:

Discard unused product 28 days after first broaching vial.

Dogs: Musculoskeletal disorders: Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4mL/10kg bodyweight). A suitable meloxicam suspension product may be used for continuation of treatment beginning after 24 hours.

Reduction of post-operative pain: Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (ie. 0.4mL/10kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Cats: Reduction of post-operative pain: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e. 0.06 mL/kg bodyweight) directly prior to induction of anaesthesia.

Management of febrile conditions: Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (i.e. 0.06 mL/kg bodyweight).

FIRST AID: If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131 126.

Dispose of empty container by wrapping with paper and putting in garbage.

Store below 25°C (Air conditioning). Protect from light.

Presentation

10mL, 20mL or 100mL multidose vials.

Norbrook Laboratories Australia Pty Limited
ACN 080 972 596
Unit 7/15-21 Butler Way, Tullamarine, VIC 3043
Free call: 1800 665 866

APVMA 62882/44177

015411102



Norbrook[®]